Storia in 4 fonti

Biogen advances Alzheimer's drug to late-stage trial despite disappointing data

Biogen said signals sugget the treatment decreases levels of tau and slows cognitive decline, particularly at the lowest dose.

Raccontata da

Confronto fonti

4 prospettive sulla stessa storia

AI · summaries

cnbc.comStai leggendo1 mesi fa

Biogen advances Alzheimer's drug to late-stage trial despite disappointing data

Biogen said signals sugget the treatment decreases levels of tau and slows cognitive decline, particularly at the lowest dose.

originale

biopharmadive.com1 mesi fa

Biogen pushing tau drug forward despite Alzheimer’s study failure

One of the company’s more closely watched research assets, BIIB080 is now heading to late-stage testing based on “the strength of the biomarker and efficacy data” seen in a Phase 2 trial.

Leggi questa versione → originale

statnews.com1 mesi fa

Biogen's tau-targeting Alzheimer's drug posts mixed results in mid-stage study

Biogen is moving its tau-targeting Alzheimer's drug into Phase 3 studies, despite mixed data from a Phase 2 trial.

Leggi questa versione → originale

endpoints.news1 mesi fa

Updated: Biogen won’t be ‘impulsive’ with anti-tau Alzheimer’s drug

Biogen reported heavily anticipated Alzheimer’s data, saying its tau-targeting drug BIIB080 missed its primary endpoint in a Phase 2 study but showed other signs of benefit.

Leggi questa versione → originale

Biogen advances Alzheimer's drug to late-stage trial despite disappointing data

Confronto fonti

Biogen advances Alzheimer's drug to late-stage trial despite disappointing data

Biogen pushing tau drug forward despite Alzheimer’s study failure

Biogen's tau-targeting Alzheimer's drug posts mixed results in mid-stage study

Updated: Biogen won’t be ‘impulsive’ with anti-tau Alzheimer’s drug

Timeline cronologica

Biogen pushing tau drug forward despite Alzheimer’s study failure

Biogen's tau-targeting Alzheimer's drug posts mixed results in mid-stage study

Updated: Biogen won’t be ‘impulsive’ with anti-tau Alzheimer’s drug

Biogen advances Alzheimer's drug to late-stage trial despite disappointing data

Biogen advances Alzheimer's drug to late-stage trial despite disappointing data

Confronto fonti

Biogen advances Alzheimer's drug to late-stage trial despite disappointing data

Biogen pushing tau drug forward despite Alzheimer’s study failure

Biogen's tau-targeting Alzheimer's drug posts mixed results in mid-stage study

Updated: Biogen won’t be ‘impulsive’ with anti-tau Alzheimer’s drug

Timeline cronologica

Biogen pushing tau drug forward despite Alzheimer’s study failure

Biogen's tau-targeting Alzheimer's drug posts mixed results in mid-stage study

Updated: Biogen won’t be ‘impulsive’ with anti-tau Alzheimer’s drug

Biogen advances Alzheimer's drug to late-stage trial despite disappointing data